Objective To investigate the therapeutic effect of telbivudine combined with Fuzheng Huayu tablets in the treatment of liver fibrosis in chronic hepatitis B ( CHB) . Methods A total of 120 patients with CHB, who were admitted to our hospital from July 2011 to November 2012, were randomly divided into treatment group ( n = 60) and control group ( n = 60) . All patients received antiviral and liver-protecting therapy with telbivudine; meanwhile, the treatment group was given Fuzheng Huayu tablets as an addition for 6 months. The liver function, four indices for liver fibrosis, and patient' s symptoms and signs were evaluated. The enumeration data were analyzed by chi-square test, and the measurement data were analyzed by t- test. Results After 6 months of treatment, the treatment group showed normalized aspartate aminotransferase ( AST) , albumin / globulin ratio ( A / G) , and total bilirubin ( TBil) as well as decreased alanine aminotransferase ( ALT) , and there were significant differences between the treatment group and control group in AST ( 33. 1 ± 15. 5 vs 39. 5 ± 18. 4, t = 2. 060, P < 0. 05) , A / G ( 1. 78 ± 0. 41 vs 1. 64 ± 0. 32, t = 2. 085, P < 0. 05) , TBil ( 13. 8 ± 6. 6 vs 17. 9 ± 8. 3, t = 3. 172, P <0. 05) , and ALT ( 55. 3 ± 23. 4 vs 64. 7 ± 27. 6, t = 2. 012, P < 0. 05) ; also, the treatment group showed significant improvements in hyaluronic acid ( HA) , laminin ( LN) , type Ⅲ procollagen peptide ( PⅢP) , and type Ⅳ collagen ( Ⅳ- C) , and there were significant differences between the treatment group and control group in HA ( 107. 7 ± 82. 3 vs 141. 6 ± 91. 4, t = 2. 155, P < 0. 05) , LN ( 125. 4 ± 73. 2 vs154. 9 ± 76. 5, t = 2. 135, P < 0. 05) , PⅢP ( 0. 61 ± 0. 56 vs 0. 96 ± 0. 44, t = 3. 266, P < 0. 05) , and IV- C ( 90. 6 ± 78. 3 vs 134. 3 ±67. 9, t = 3. 807, P < 0. 05) . In addition, the treatment group had alleviated lassitude, improved appetite, and palliated abdominal distension, demonstrating significant differences compared with the control group ( 71. 7% vs 53. 3%, P < 0. 05; 83. 3% vs 65. 0%, P < 0. 05;80. 0% vs 58. 3%, P < 0. 05) . Conclusion When used along with Fuzheng Huayu tablets, telbivudine has better performances in relieving symptoms, improving liver function, and reducing liver fibrosis in CHB patients with liver fibrosis.
检验项目参考区间是临床疾病诊断与健康监测的主要依据,参考区间的准确性、适用性直接影响着临床判断。2012年,我国卫生行业标准发布了血清AST、ALT、GGT、ALP等项目的参考区间,同时指出该参考区间可能受民族、地区影响而致其不适用,各实验室可自行建立参考区间[1]。目前建立参考区间的方法有直接法[2]和间接法[3],直接法需通过建立严格的排除标准而筛选符合要求的参考个体,且此法过程漫长繁琐、难以实施;而间接法只需通过数学统计,凭借快速简便、能得到与直接法相似结果的优势脱颖而出。本研究利用临床实验室信息系统(laboratory information system,LIS)已有数据,用数学统计模型建立AST、ALT、GGT、ALP间接法参考区间,并与国家行业标准比较,以期为临床疾病诊断与健康监测提供依据和参考。
[1]ZHONG W, XIE WF.New strategy for the treatment of hepatic fibrosis[J].J Clin Hepatol, 2011, 27 (3) :233-235. (in Chinese) 钟巍, 谢渭芬.肝纤维化治疗新策略[J].临床肝胆病杂志, 2011, 27 (3) :233-235.
[2]FANG Q, AI L, LIU YK.Observation of clinical effect and safety evaluation of a 48 week trial of Telbivudine in patients with chronic hepatitis B of hepatitis B e antigen-positive[J].China Med Herald, 2012, 9 (9) :89-91. (in Chinese) 方清, 艾丽, 刘幼昆.替比夫定治疗乙型肝炎e抗原阳性慢性乙型肝炎48周疗效观察和安全性评价[J].中国医药导报, 2012, 9 (9) :89-91.
[3]LUO SQ.Recent advance of telbivudine for the treatment of chronic hepatitis B[J].Chin J New Drugs, 2008, 17 (18) :626-629. (in Chinese) 罗生强.替比夫定治疗慢性乙型肝炎的新进展[J].中国新药杂志, 2008, 17 (18) :626-629.
[4]LIU Y, LIU P, LIU CH.Proteomic analysis of proliferation and apoptosis in carbon tetrachloride induced rat liver fibrosis[J].Chin J Hepatol, 2005, 13 (8) :563-567. (in Chinese) 刘莺, 刘平, 刘成海.细胞增殖与凋亡相关蛋白质在大鼠肝纤维化形成与消减中的动态变化[J].中华肝脏病杂志, 2005, 13 (8) :563-567.
[5]LIU CH, HU YY, XU LM, et al.Effect of Fuzhenghuayu formula and its action against liver fibrosis[J].China J Chin Mater Med, 2009, 11 (4) :12-22. (in Chinese) 刘成海, 胡义扬, 徐列明, 等.扶正化瘀方抗肝纤维化的作用和影响[J].中国中药杂志, 2009, 11 (4) :12-22.
[6]WANG QL, TAO YY, SHEN L, et al.Chinese herbal medicine Fuzheng Huayu recipe inhibits liver fibrosis by mediating the transforming growth factor-β1 Smads signaling pathway[J].J Chin Integr Med, 2012, 10 (5) :561-569. (in Chinese) 王清兰, 陶艳艳, 沈丽, 等.扶正化瘀方影响转化生长因子β1/Smad信号通路的抗肝纤维化作用机制[J].中西医结合学报, 2012, 10 (5) :561-569.
[7]ZHAO WL, CHENG H, YANG ZM.Effects of combination therapy of matrine with adefovir dipivoxil on hepatic fibrosis in patients with chronic hepatitis B[J].J Clin Hepatol, 2011, 27 (5) :490-492. (in Chinese) 赵文莉, 程红, 杨忠民.阿德福韦酯联合苦参素治疗慢性乙型肝炎患者对肝纤维化指标的影响[J].临床肝胆病杂志, 2011, 27 (5) :490-492.
[8]LIU P.Prevention and treatment of hepatic fibrosis[J].Chin J Hepatol, 2000, 8 (4) :242. (in Chinese) 刘平.肝纤维化的防治[J].中华肝脏病杂志, 2000, 8 (4) :242.
[9]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment of chronic hepatitis B[J].J Clin Hepatol, 2006, 22 (1) :3-15. (in Chinese) 中华医学会肝病学分会、中华医学会、感染病学分会.慢性乙型肝炎防治指南[J].临床肝胆病杂志, 2006, 22 (1) :3-15.
WANG YT, LI XW, XING DY, et al. Establishment of the reference intervals of four biochemical parameters for liver function among adults in Changchun, China based on the indirect method[J]. J Clin Hepatol, 2021, 37(9): 2161-2166. DOI: 10.3969/j.issn.1001-5256.2021.09.030.
WANG YT, LI XW, XING DY, et al. Establishment of the reference intervals of four biochemical parameters for liver function among adults in Changchun, China based on the indirect method[J]. J Clin Hepatol, 2021, 37(9): 2161-2166. DOI: 10.3969/j.issn.1001-5256.2021.09.030.